Literature DB >> 19917682

Cutting edge: requirement of MARCH-I-mediated MHC II ubiquitination for the maintenance of conventional dendritic cells.

Mari Ohmura-Hoshino1, Yohei Matsuki, Mari Mito-Yoshida, Eiji Goto, Masami Aoki-Kawasumi, Manabu Nakayama, Osamu Ohara, Satoshi Ishido.   

Abstract

MARCH-I (membrane-associated RING-CH I) has been suggested as a physiological E3 ubiquitin ligase for both MHC class II (MHC II) and B7-2. In this study, we show that MARCH-I-mediated MHC II ubiquitination is necessary for the maintenance of conventional dendritic cell (cDC) functions in the steady state. MARCH-I-deficient cDCs accumulated MHC II and B7-2 and exhibited low Ag-presenting ability for exogenous Ags and low cytokine-producing ability upon stimulation in vivo. Importantly, MHC II, but not B7-2, was required for impaired cDC function induced by loss of MARCH-I in vivo. Moreover, MHC II knockin mice whose MHC II was not ubiquitinated showed dysfunction of cDC similar to that of MARCH-I knockout mice. These results suggest that the accumulation of MHC II resulting from loss of ubiquitination caused cDC abnormality; therefore, MARCH-I may function as a housekeeper of cDC in the steady state.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917682     DOI: 10.4049/jimmunol.0902178

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

Review 1.  Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways.

Authors:  Laurence C Eisenlohr; Nancy Luckashenak; Sebastien Apcher; Michael A Miller; Gomathinayagam Sinnathamby
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

2.  Ubiquitination regulates MHC class II-peptide complex retention and degradation in dendritic cells.

Authors:  Even Walseng; Kazuyuki Furuta; Berta Bosch; Karis A Weih; Yohei Matsuki; Oddmund Bakke; Satoshi Ishido; Paul A Roche
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

Review 3.  MHC class II antigen presentation by dendritic cells regulated through endosomal sorting.

Authors:  Toine ten Broeke; Richard Wubbolts; Willem Stoorvogel
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

Review 4.  MHC class II fine tuning by ubiquitination: lesson from MARCHs.

Authors:  Satoshi Ishido; Mizuho Kajikawa
Journal:  Immunogenetics       Date:  2018-10-31       Impact factor: 2.846

5.  Encounter with antigen-specific primed CD4 T cells promotes MHC class II degradation in dendritic cells.

Authors:  Kazuyuki Furuta; Satoshi Ishido; Paul A Roche
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-05       Impact factor: 11.205

6.  Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing.

Authors:  Daimon P Simmons; Pamela A Wearsch; David H Canaday; Howard J Meyerson; Yi C Liu; Ying Wang; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

7.  Tollip-induced down-regulation of MARCH1.

Authors:  Marie-Claude Bourgeois-Daigneault; Abdul Mohammad Pezeshki; Tristan Galbas; Mathieu Houde; Martin Baril; Klaus Früh; Abdelaziz Amrani; Satoshi Ishido; Daniel Lamarre; Jacques Thibodeau
Journal:  Results Immunol       Date:  2013-02-20

8.  A major isoform of the E3 ubiquitin ligase March-I in antigen-presenting cells has regulatory sequences within its gene.

Authors:  Sunil Kaul; Sharad K Mittal; Paul A Roche
Journal:  J Biol Chem       Date:  2018-01-29       Impact factor: 5.157

9.  Membrane-Associated RING-CH proteins associate with Bap31 and target CD81 and CD44 to lysosomes.

Authors:  Eric Bartee; Craig A Eyster; Kasinath Viswanathan; Mandana Mansouri; Julie G Donaldson; Klaus Früh
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

Review 10.  Molecular control of steady-state dendritic cell maturation and immune homeostasis.

Authors:  Gianna Elena Hammer; Averil Ma
Journal:  Annu Rev Immunol       Date:  2013-01-17       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.